19/09/2025
Nasal spray for Heart/Liver/Kidneys
🚨The FDA just approved a nasal spray that could prevent over 1 million hospitalizations a year for heart, liver, and kidney disease!
A groundbreaking new treatment for fluid retention caused by heart, liver, and kidney disease has received FDA approval, marking a major step toward more accessible care.
Enbumyst, a nasal spray formulation of the loop diuretic bumetanide, is the first of its kind approved in the U.S. for treating edema outside hospital settings. Developed by Corstasis Therapeutics, the spray is designed for adults managing chronic illnesses that frequently result in fluid overload—conditions that lead to over one million hospitalizations annually. Unlike oral medications, which often suffer from poor absorption, and IV treatments that require clinical administration, Enbumyst delivers fast-acting relief through a self-administered nasal spray.
Clinical trials demonstrated that the nasal spray’s efficacy is on par with IV diuretics, with rapid absorption and a consistent diuretic response. This could allow healthcare providers to intervene earlier and patients to manage their conditions more effectively at home, potentially reducing hospital readmissions and easing healthcare costs. With a solid safety profile and common side effects like dizziness and nausea, Enbumyst is poised to become a game-changer, especially for heart failure patients. The drug is expected to hit the market in late 2025, potentially reshaping outpatient care for millions.
Source: Thompson, B. (2025, September 15). FDA approves first nasal spray diuretic for heart, liver and kidney disease. New Atlas.
Courtesy: Hashem Al-Ghaili
